Anti-angiogenic therapy for metastatic colorectal cancer - analysis of date from two centers

Abstract

Bevacizumab is a common part of the first line treatment of patients with mCRC in the Czech Republic. It should be the main point of interest to find the predictive factors of efficasy because of the high treatment expenses.

Keywords

• Colorectal cancer
• bevacizumab
• prognostic factors